From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Clinical data
ATC code
  • None
CAS Number
PubChem CID
Chemical and physical data
Formula C17H20ClN5O3
Molar mass 377.825 g/mol
3D model (JSmol)

Dasolampanel (INN, USAN, code name NGX-426) is an orally bioavailable analog of tezampanel and thereby competitive antagonist of the AMPA and kainate receptors which was under development by Raptor Pharmaceuticals/Torrey Pines Therapeutics for the treatment of chronic pain conditions including neuropathic pain and migraine.[1] It was developed as a follow-on compound to tezampanel, as tezampanel is not bioavailable orally and must be administered by intravenous injection,[2][3] but ultimately neither drug was ever marketed.

See also[edit]


  1. ^ Ian P. Stolerman (31 July 2010). Encyclopedia of Psychopharmacology. Springer Science & Business Media. pp. 514–. ISBN 978-3-540-68698-9. 
  2. ^ Jes Olesen; Nabih Ramadan (21 August 2008). Innovative Drug Development for Headache Disorders. Oxford University Press. pp. 188–. ISBN 978-0-19-955276-4. 
  3. ^ Gary S. Firestein; Ralph Budd; Sherine E Gabriel; James R O'Dell; Iain B. McInnes (31 August 2012). Kelley's Textbook of Rheumatology: Expert Consult Premium Edition: Enhanced Online Features. Elsevier Health Sciences. pp. 1031–. ISBN 1-4557-3767-4.